ANAPTYSBIO, INC - 20 Apr 2026 Form 4 Insider Report for First Tracks Biotherapeutics, Inc. (TRAX)

Reporting relationship: 10%+ Owner
Issuer ticker: TRAX
Reported as of: 20 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 Apr 2026, 16:05:12 UTC
Prior SEC filing: 01 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Dan Faga, Chief Executive Officer and President of AnaptysBio, Inc.

Key filing fact

ANAPTYSBIO, INC filed Form 4 for First Tracks Biotherapeutics, Inc. (TRAX) on 22 Apr 2026.

Key facts

This page summarizes ANAPTYSBIO, INC's Form 4 filing for First Tracks Biotherapeutics, Inc. (TRAX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 22 Apr 2026, 16:05.

Change

Previous filing in this sequence was filed on 01 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001370053 Primary reporting owner

ANAPTYSBIO, INC

Relationship: 10%+ Owner
Address: 10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO
Signature: /s/ Dan Faga, Chief Executive Officer and President of AnaptysBio, Inc.
Signature date: 22 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TRAX transaction

Common Stock, par value $0.001 per share

Other

Transaction value
Shares: -100
Change %: -100%
Price
Shares after: 0
Date: 20 Apr 2026
Ownership: Direct
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

On April 1, 2026, AnaptysBio, Inc., a Delaware corporation ("AnaptysBio"), reported that it owned 100 shares of common stock, par value $0.001 per share, of First Tracks Biotherapeutics, Inc. ("First Tracks"), which at the time constituted all of the issued and outstanding shares of common stock of First Tracks.

Footnote F2

The record date for the distribution by AnaptysBio of all shares of common stock of First Tracks to the holders of AnaptysBio common stock was April 20, 2026 (the "Spin-Off"). The Spin-Off occurred before the market opened on April 20, 2026.

Footnote F3

Represents the outstanding shares of common stock of First Tracks as of April 20, 2026, which were distributed in the Spin-Off as defined in footnote 2 on April 20, 2026.